
-
Oasis star Noel Gallagher piles praise on 'amazing' brother Liam
-
German minister says China's 'assertiveness' threatens European interests
-
Markets waver as Japan exports show tariff strain
-
Afghanistan bus crash death toll rises to 78
-
Historic Swedish church inches closer to new home
-
Asian markets waver as Japan exports show tariff strain
-
Israel defence minister approves plan to conquer Gaza City
-
More than 20 dead in fresh Pakistan monsoon rains
-
Brazilian goalkeeper Fabio claims world record for most games
-
Vienna chosen to host Eurovision 2026
-
Japan hosts African leaders for development conference
-
Reclusive Turkmenistan bids to go tobacco-free in 2025
-
From TikTok to frontrunner, inside Paz's presidential campaign in Bolivia
-
Chinese mega-hit 'Ne Zha II' enlists Michelle Yeoh to woo US audiences
-
India celebrates clean energy milestone but coal still king
-
US demand for RVs fuels deforestation on Indonesia's Borneo: NGOs
-
Kneecap rapper faces court on terror charge over Hezbollah flag
-
Dutch divers still haul up debris six years after container spill
-
Asian markets dip after US tech slide
-
NZ soldier sentenced to two years' detention for attempted espionage
-
Time to Go: Japan pro board game player retires at 98
-
City girls snub traditional Hindu face tattoos in Pakistan
-
Australia lashes Netanyahu over 'weak' leader outburst
-
Polar bear waltz: Fake Trump-Putin AI images shroud Ukraine peace effort
-
Sounds serious: NYC noise pollution takes a toll
-
Trump slams US museums for focus on 'how bad slavery was'
-
US agrees to talks with Brazilian WTO delegates on tariffs
-
Israel-France row flares over Macron's move to recognise Palestinian state
-
DEA Unconstitutional Marijuana Playbook: How the DEA Is Repeating the DOL's Mistakes Against MMJ BioPharma
-
Nano One Successfully Commissions Proprietary Agitator Equipment Boosting Throughput Capacity at Candiac Five New Patents Added to Global IP Portfolio
-
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
-
Tocvan Strengthens Team Appoints Christopher Gordon As Head Of Corporate Development
-
ANGLE Announces Collaboration with Myriad Genetics
-
White House starts TikTok account as platform in US legal limbo
-
Syrian, Israeli diplomats met in Paris to discuss 'de-escalation': report
-
Wanyonyi, the former cattle herder ready to eclipse Rudisha
-
Swiatek, Ruud romp into US Open mixed doubles semis, Alcaraz, Djokovic out
-
Mbappe lifts Real Madrid past Osasuna in La Liga opener
-
Venezuela says 66 children 'kidnapped' by the United States
-
Brazil nixes red World Cup jersey amid political outcry
-
Real Madrid scrape past Osasuna in La Liga opener
-
McIlroy backs 'clean slate' season finale format change
-
'Call of Duty', 'Black Myth' wow Gamescom trade show
-
Isak says 'change' best for everyone after Newcastle trust broken
-
Salah makes history with third PFA player of the year award
-
Rabiot, Rowe put up for sale by Marseille after bust-up
-
Weary Swiatek wins US Open mixed doubles opener
-
Miami fearing Messi blow ahead of Leagues Cup quarter-finals
-
Trump rules out US troops but eyes air power in Ukraine deal
-
Trump course back on PGA schedule for 2026 season: tour

DEA's Thomas Prevoznik Fails Again: Cannabis Users Poisoned While Pharmaceutical Cannabis Remains Blocked
While the DEA's Thomas Prevoznik Turned a Blind Eye, American Cannabis Users Were Poisoned: How the DEA Regulatory Failure and Inaction Enabled a Public Health Crisis.
WASHINGTON, D.C. / ACCESS Newswire / July 4, 2025 / The Drug Enforcement Administration (DEA) is asleep at the wheel - or worse, willfully negligent - as contaminated cannabis floods state markets, consumers are poisoned, and legitimate pharmaceutical research is actively blocked by the very agency tasked with protecting public health.

At the center of this national disgrace is DEA's Deputy Administrator Thomas Prevoznik, the long-time bureaucrat at the helm of the DEA's Diversion Control Division. While Prevoznik parades around on taxpayer-funded panels pretending to safeguard public safety, the truth is undeniable: the DEA has utterly failed its mission. As stated on the DEA website:
"The mission of DEA's Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs".
State Cannabis Chaos Exposes DEA Incompetence
The latest scandal comes out of Massachusetts, where state regulators just suspended the license of Assured Testing Laboratories -one of the largest cannabis labs in the state-after uncovering what they describe as an "intentional effort to conceal" failing safety results on cannabis products.
The lab, which tested 25% of all cannabis in the state, was caught falsifying reports, hiding contamination, and greenlighting dangerous products that should have failed mandatory yeast, mold, and microbial standards. Thousands of cannabis products were put into consumer hands without accurate safety testing.
Yet not a word from the DEA.
Not a single enforcement action.
No national recall.
No intervention.
The DEA's Mission: Betrayed from Within
The DEA's own mission is crystal clear:
"To prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs."
Under Prevoznik's failed leadership, that mission has become a farce.
The DEA has allowed state cannabis markets to operate as the Wild West: no national oversight, no quality control, no consistency.
Consumers across the U.S. are being exposed to tainted, contaminated cannabis products, while the DEA turns a blind eye.
At the same time, the DEA is actively blocking federally compliant pharmaceutical cannabis development including MMJ BioPharma's FDA-approved clinical research for devastating conditions like Huntington's Disease and Multiple Sclerosis.
Why Is Prevoznik Blocking Science While Allowing Poison?
The hypocrisy is staggering:
The DEA refuses to grant a federal manufacturing license to MMJ BioPharma, whose plant-derived, pharmaceutical-grade cannabis medicines are produced under strict FDA standards.
Meanwhile, Prevoznik's division permits contaminated street level cannabis to flood state markets with no uniform standards, no federal action, and no public warning.
It's the worst of both worlds:
The public is unprotected and medical innovation is obstructed.
The Human Cost of Prevoznik's Failures
Families with children suffering from intractable epilepsy, cancer, or neurological disorders are denied access to standardized, pharmaceutical cannabis because the DEA won't act.
At the same time, recreational markets pump out high-potency THC products riddled with mold, pesticides, and unregulated contaminants: products that in some cases are making people sick.
This is not regulation.
This is dereliction of duty.
Time for Accountability: Fire Prevoznik, Reform DEA
The solution is clear:
Thomas Prevoznik must be immediately removed from his position for gross negligence and regulatory malpractice.
The DEA's obstruction of pharmaceutical cannabis research must end.
Oversight of cannabis research should be transferred to agencies that understand science-such as the FDA or NIH.
Congress must investigate how the DEA has allowed the national cannabis market to devolve into chaos while blocking life-saving medicines from reaching patients.
"The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence," said Duane Boise, CEO of MMJ BioPharma Cultivation .
"It's time for the DEA to be held accountable for decades of failure."
The American People Deserve Better
The DEA exists to serve and protect the public, not to act as a political roadblock while Americans are poisoned and scientific progress is stalled.
Prevoznik failed. The DEA failed.
It's time for Congress, the courts, and the public to take back control.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
M.Fischer--AMWN